Recent Updates
Recently added Catalysts
AMIX Positive Sentiment Score: 70/100

Autonomix Medical, Inc. Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

Key Takeaway: Autonomix Medical, Inc. (AMIX) participated in the Virtual Investor 'What’s Your Story' Summer Spotlight On-Demand Conference. CEO Brad Hauser highlighted his commitment to the company's innovative technology aimed at revolutionizing the diagnosis and treatment of nervous system diseases. The company's platform technology features a catheter-based microchip sensing array that could significantly improve the detection of neural signals. Autonomix is focusing on developing this technology for conditions such as pancreatic cancer, which currently has no reliable treatment options.

Market Sentiment Analysis

POSITIVE FACTORS

  • CEO Brad Hauser expressed passion for innovative technology.
  • Company focuses on improving diagnosis and treatment of nervous system diseases.
  • Technology is aimed at addressing conditions like pancreatic cancer, which lacks reliable solutions.

Full Press Release Details

– Video webcast now available on-demand
THE WOODLANDS, TX, July 22, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Brad Hauser, Chief Executive Officer of Autonomix, participated in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference.
For the event, Mr. Hauser dove deeper into his dedication to the Company, how he got to where he is today, and provided insight into why he is passionate about the Company’s innovative technology.
The on-demand video webcast is now available on the Virtual Investor website as well as the Events page under the Investors section of the Company’s website (autonomix.com).
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact

Tags

medical device company

Frequently Asked Questions

Where can I watch the on-demand video webcast?

The on-demand video webcast is available on the Virtual Investor website.

What is the focus of Autonomix Medical, Inc.?

Autonomix is focused on advancing technologies for diagnosing and treating nervous system diseases.

What technology is Autonomix developing?

Autonomix is developing a catheter-based microchip sensing array for neural signal detection.

What condition is Autonomix's initial trials focused on?

Initial trials are focused on pancreatic cancer and its associated pain.

Is Autonomix's technology approved for marketing in the US?

No, the technology is investigational and has not been cleared for marketing in the US.

Last updated: Jul 22, 2025